Hemodynamics, fluids & transfusion
Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients a systematic review and meta-analysis of randomized controlled trials
Pooled result · MortalityResult — go to the resultRelative risk 1.01 95% CI 0.90–1.13Authors' conclusion
This systematic review and meta-analysis fail to support escalated anticoagulation doses to reduce mortality in critically ill COVID-19 patients.
Study context
- Population
- Critically ill patients with severe COVID-19
- Participants
- 2,130 patients · 6 randomized controlled trials (RCTs)
- Comparison
- Escalated vs standard prophylactic doses of heparins
- Outcome
- Mortality
Pooled result
As reported in the abstract
Relative risk
1.01
95% CI 0.90–1.13
Escalated dose vs Standard thromboprophylaxis
RR 1.01 (95% CI 0.90–1.13)
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| DVT | 0.81 (0.61–1.08) | |
| PE | 0.35 (0.21–0.60) | |
| 0.20.5125Relative risk (log scale) |
Safety
| Outcome | RR (95% CI) | |
|---|---|---|
| Bleeding eventsIncreased risk | 1.65 (1.08–2.53) | |
| 0.20.5125Relative risk (log scale) |
Original publication
Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients a systematic review and meta-analysis of randomized controlled trials. J Crit Care. Published 25 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →